Immunology

The Immunology Department at St James’s hospital  runs a number of both investigator-led and industry centered drug trials in Immunology.

Current Trials & Studies
Study NameStudy TitleStudy TypeSponsorSponsor Type
CDZAn open-label, non-randomized, within-patient dose-finding study followed by a randomized, subject, investigator and sponsor-blinded placebo controlled study to assess the efficacy and safety of CDZ173 in patients with APDS/PASLI (Activated phosphoinositide 3-kinase delta syndrome/ p110δ-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency)Clinical TrialNovartisCommercial: Industry
CDZ OLEAn open-label, non-randomized extension study to evaluate the long term safety, tolerability, efficacy and pharmacokinetics of CDZ173 in patients with APDS/PASLI (Activated phosphoinositide 3-kinase delta syndrome/ p110δ-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency)Clinical TrialNovartisCommercial: Industry
HyQviaNon-interventional Post-Authorization Safety Study on the Long-Term Safety of HyQvia in Subjects treated with HyQviaObservational with radiology or blood testsBaxaltaCommercial: Industry
IOS registryIcatibant Outcome Survey (IOS) registry protocolObservational-non invasiveShireCommercial: Industry
ABT in UrticariaHealth through attention based training (ABT) for patients in SJH with urticariaObservational-non invasiveNon-commercial: Academic